Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

Phase 4

Recruiting

• Conditions: Kidney Transplant Immunosuppression
• Interventions: Drug: Mizoribine; Drug: Mycophenolate Mofetil

• Registration Number: NCT06114953
• Lead Sponsor: Lee's Pharmaceutical Limited

Brief Summary

This prospective, randomized controlled study is intended to enroll 152 patients in the early stages of donor kidney transplantation at six clinical centers in China between January 2023 and January 2024. All patients meeting the inclusion criteria were randomly assigned 1:1 to either Mizoribine or Mycophenolate Mofetil for 12 months. At the baseline of foll...

Detailed Description

This is a multi-center, prospective, non-inferior, randomized controlled clinical study. The sick individuals and their families participating in the trial voluntarily participate and sign the "informed consent" under the premise of fully understanding the treatment plan; The treatment plan was approved by the hospital ethics committee.
...

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2023-01-01
• Status Verified: 2023-10
• Study First Submitted: 2023-10-24
• Study First Submitted QC: 2023-10-30
• Last Update Submitted: 2023-10-30
• Study First Posted: 2023-11-02
• Last Update Posted: 2023-11-02
• Primary Completion: 2025-01-01
• Study Completion: 2025-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

• 1. After donor kidney transplantation;
• 2. Adult recipients aged 18-75 years, regardless of gender;
• 3. First-time kidney transplant recipients;
• 4. Voluntarily sign written informed consent.

Read More

Exclusion Criteria

• 1. Multiple organ transplantation;
• 2. DSA positive patients had ABO incompatibility and PRA>30%;
• 3. Recipients with active signs of infection;
• 4. Recipients with leukocyte counts below 3,000/mm3;
• 5. Pregnant women, breastfeeding women or women who do not wish to use appropriate contraceptive methods during the study period;
• 6. Patients with severe gastrointestinal diseases and active peptic ulcer disease;
• 7. suffering from any mental illness;
• 8. Patients with severe heart disease and abnormal heart function;
• 9. Subjects who are known to be allergic to the test drug;
• 10. Recipients judged unsuitable for inclusion by other competent physicians.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Mizoribine group	Mizoribine	Mizoribine, glucocorticoid, tacrolimus
Mycophenolate group	Mycophenolate Mofetil	Mycophenolate mofetil, glucocorticoid, tacrolimus

Primary Outcome Measures

Name	Time	Method
Serum creatinine	Postoperative 1 week, 2 weeks, 1month, 2，3，6，9，12 months	Monitoring serum creatinine.

Trial Locations

Locations (6)

Affiliated Hospital of Guizhou Medical University; 🇨🇳 Guiyang, Guizhou, China

First Affiliated Hospital of Zhengzhou University; 🇨🇳 Zhengzhou, Henan, China

The Second Affiliated Hospital of Guangxi Medical University; 🇨🇳 Nanning, Guangxi, China

Beijing Friendship Hospital, Capital Medical University; 🇨🇳 Beijing, China

West China Hospital, Sichuan University; 🇨🇳 Chengdu, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China